Sugi Predict

Sugi Predict / Compounds / SCHEMBL75416

SCHEMBL75416

SCHEMBL75416

Fc1ccc(C(F)(F)F)c(CBr)c1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 3/20 0.46
▸ SLC6A2 P23975 5/20 0.44
▸ SLC6A4 P31645 5/20 0.44
▸ P2RX7 Q99572 2/20 0.37
▸ CHRM5 P08912 1/20 0.37
▸ NTRK1 P04629 2/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ KIF11 P52732 2/20 0.33
▸ TRPA1 O75762 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29616489 0.88 IDO1 (0.59) IDO1SLC6A2SLC6A4P2RX7SLC6A3
SCHEMBL488748 0.88 IDO1 (0.59) IDO1SLC6A2SLC6A4P2RX7SLC6A3
SCHEMBL6152758 0.81 IDO1 (0.50) IDO1SLC6A2SLC6A4P2RX7CHRM5
SCHEMBL30448721 0.79 KDM1A (0.40) IDO1SLC6A4CYP11B2
SCHEMBL21403423 0.79 IDO1 (0.46) IDO1SLC6A2SLC6A4P2RX7CHRM5
SCHEMBL295918 0.79 IDO1 (0.50) IDO1SLC6A2SLC6A4P2RX7CHRM5
SCHEMBL18149164 0.79 KDM1A (0.40) IDO1SLC6A4CYP11B2
SCHEMBL29875850 0.79 IDO1 (0.46) IDO1SLC6A2SLC6A4P2RX7CHRM5
SCHEMBL1775557 0.79 CES2 (0.46) IDO1
SCHEMBL938117 0.79 IDO1 (0.46) IDO1SLC6A2SLC6A4P2RX7CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110698432-B Benzyl piperazine compound, preparation method thereof and application thereof in antivirus 中国医学科学院医药生物技术研究所 2023-02-03 — — CN claimed
WO-2021102600-A1 BENZYL PIPERAZINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN ANTIVIRUS 中国医学科学院医药生物技术研究所 2021-06-03 — — WO claimed
CN-110698432-A Benzyl piperazine compound, preparation method thereof and application thereof in antivirus 中国医学科学院医药生物技术研究所 2020-01-17 — — CN claimed
US-20250122171-A1 Substituted Amine Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. 2025-04-17 — — US disclosed
WO-2025064534-A1 SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2025-03-27 — — WO disclosed
US-20240174649-A1 CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2024-05-30 — — US disclosed
US-11939307-B2 Phenylmethyl-piperazine derivatives and antiviral uses thereof INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2024-03-26 — — US disclosed
CN-110698432-B Benzyl piperazine compound, preparation method thereof and application thereof in antivirus 中国医学科学院医药生物技术研究所 2023-02-03 — — CN disclosed
US-20230024612-A1 BENZYL PIPERAZINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN ANTIVIRUS INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-01-26 — — US disclosed
WO-2022165432-A1 CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-08-04 — — WO disclosed
WO-2021102600-A1 BENZYL PIPERAZINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN ANTIVIRUS 中国医学科学院医药生物技术研究所 2021-06-03 — — WO disclosed
US-6777409-B2 FOR THERAPY OF INFLAMMATION SCHERING AKTIENGESELLSCHAFT PATENTS (DE) 2004-08-17 — — US disclosed
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC 2003-11-06 — — US disclosed
CN-1444570-A Non-steroidal anti-inflammatory drugs SCHERING AG (DE) 2003-09-24 — — CN disclosed
WO-2003057688-A2 OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS PFIZER JAPAN INC. (JP) 2003-07-17 — — WO disclosed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 — — EP disclosed
EP-1309571-A1 NON-STEROIDAL INFLAMMATION INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-05-14 — — EP disclosed
US-20020077356-A1 Nonsteroidal antiinflammatory agents SCHERING AKTIENGESELLSCHAFT (DE) 2002-06-20 — — US disclosed
WO-2002010143-A1 NON-STEROIDAL INFLAMMATION INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2002-02-07 — — WO disclosed
EP-1081137-A1 Selective inhibitors of aggrecanase in osteoarthritis treatment Pfizer Products Inc. (US) 2001-03-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077356-A1 Nonsteroidal antiinflammatory agents PTGS1, PTGES2, PTGES IDO1 500/4885SLC6A2 4303/4885SLC6A4 3556/4885
US-20230024612-A1 BENZYL PIPERAZINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN ANTIVIRUS ZC3HAV1, ZC3HAV1L, CPSF1 IDO1 1705/4885SLC6A2 4165/4885SLC6A4 4123/4885
US-20250122171-A1 Substituted Amine Compounds, Compositions and Methods of Use MRGPRX2, MRGPRX1, MRGPRX4 IDO1 2668/4885SLC6A2 107/4885SLC6A4 254/4885
US-20240174649-A1 CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE CUL4A, CUL1, CUL3 IDO1 2287/4885SLC6A2 4621/4885SLC6A4 3983/4885
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators HRH4, HRH2, HTR4 IDO1 560/4885SLC6A2 702/4885SLC6A4 190/4885
US-11939307-B2 Phenylmethyl-piperazine derivatives and antiviral uses thereof ZC3HAV1, EIF2AK2, CPSF1 IDO1 2340/4885SLC6A2 4405/4885SLC6A4 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.